Crude Oil Rises; Onconetix Shares Spike Higher
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 27 2024
0mins
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Dow rising 0.26% while the Nasdaq and S&P 500 fell by 0.59% and 0.25%, respectively; notable movements included IonQ's shares surging 16% after a contract announcement, while Seelos Therapeutics dropped 19% due to a postponed meeting.
Global Economic Indicators: European markets closed higher with positive sentiment indicators, while Asian markets mostly rose; in the U.S., wholesale inventories increased slightly, personal income and spending rose modestly, and the trade deficit narrowed.
Analyst Views on NVNO
About NVNO
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
